Promising Results: Experimental Cancer Vaccine and Immunotherapy Combo Shows Benefits Against Melanoma

An experimental mRNA vaccine, mRNA-4157/V940, used in combination with Merck's Keytruda immunotherapy, has shown continued benefits for people with high-risk forms of melanoma. In a three-year follow-up, participants who received the vaccine along with Keytruda had a 49% lower risk of recurrence or death and a 62% lower risk of distant tumor spread or death compared to those who received Keytruda alone. The vaccine has also shown a 44% lower risk of recurrence or death and a 65% lower risk of distant metastasis or death in a two-year follow-up. The most common side effects were fatigue, pain at the injection site, and chills. Phase 3 trials are underway, and the vaccine has been granted breakthrough therapy designation by the FDA.